Your browser doesn't support javascript.
loading
Hot Melt Coating of Amorphous Carvedilol.
Bannow, Jacob; Koren, Lina; Salar-Behzadi, Sharareh; Löbmann, Korbinian; Zimmer, Andreas; Rades, Thomas.
Afiliación
  • Bannow J; Department of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
  • Koren L; Institute of Pharmaceutical Sciences/Pharmaceutical Technology and Biopharmacy, Karl-Franzens-University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.
  • Salar-Behzadi S; Institute of Pharmaceutical Sciences/Pharmaceutical Technology and Biopharmacy, Karl-Franzens-University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.
  • Löbmann K; Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, A-8010 Graz, Austria.
  • Zimmer A; Department of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
  • Rades T; Institute of Pharmaceutical Sciences/Pharmaceutical Technology and Biopharmacy, Karl-Franzens-University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.
Pharmaceutics ; 12(6)2020 Jun 06.
Article en En | MEDLINE | ID: mdl-32517255
ABSTRACT
The use of amorphous drug delivery systems is an attractive approach to improve the bioavailability of low molecular weight drug candidates that suffer from poor aqueous solubility. However, the pharmaceutical performance of many neat amorphous drugs is compromised by their tendency for recrystallization during storage and lumping upon dissolution, which may be improved by the application of coatings on amorphous surfaces. In this study, hot melt coating (HMC) as a solvent-free coating method was utilized to coat amorphous carvedilol (CRV) particles with tripalmitin containing 10% (w/w) and 20% (w/w) of polysorbate 65 (PS65) in a fluid bed coater. Lipid coated amorphous particles were assessed in terms of their physical stability during storage and their drug release during dynamic in vitro lipolysis. The release of CRV during in vitro lipolysis was shown to be mainly dependent on the PS65 concentration in the coating layer, with a PS65 concentration of 20% (w/w) resulting in an immediate release profile. The physical stability of the amorphous CRV core, however, was negatively affected by the lipid coating, resulting in the recrystallization of CRV at the interface between the crystalline lipid layer and the amorphous drug core. Our study demonstrated the feasibility of lipid spray coating of amorphous CRV as a strategy to modify the drug release from amorphous systems but at the same time highlights the importance of surface-mediated processes for the physical stability of the amorphous form.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca